A share price of Adverum Biotechnologies Inc [ADVM] is currently trading at $4.27, down -0.47%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ADVM shares have lost -0.23% over the last week, with a monthly amount drifted -0.47%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Adverum Biotechnologies Inc [NASDAQ: ADVM] stock has seen the most recent analyst activity on November 17, 2025, when H.C. Wainwright downgraded its rating to a Neutral. Previously, Oppenheimer started tracking the stock with Outperform rating on June 25, 2024, and set its price target to $25. On April 30, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $30 on the stock. Truist upgraded its rating to a Buy but stick to its price target of $4 on July 07, 2022. Cantor Fitzgerald downgraded its rating to a Neutral. SVB Leerink downgraded its rating to Mkt Perform for this stock on May 03, 2021, but kept the price target unchanged to $5. In a note dated April 29, 2021, Truist downgraded a Hold rating on this stock and revised its target price from $30 to $9.
Adverum Biotechnologies Inc experienced fluctuations in its stock price throughout the past year between $1.78 and $7.73. Currently, Wall Street analysts expect the stock to reach $4.83 within the next 12 months. Adverum Biotechnologies Inc [NASDAQ: ADVM] shares were valued at $4.27 at the most recent close of the market. An investor can expect a potential return of 13.11% based on the average ADVM price forecast.
Analyzing the ADVM fundamentals
Trailing Twelve Months sales for Adverum Biotechnologies Inc [NASDAQ:ADVM] were 0.00M which represents -100.00% decline. To continue investigating profitability, this company’s Return on Assets is posted at -2.82, Equity is -38.45 and Total Capital is -2.96. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.24 points at the first support level, and at 4.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.29, and for the 2nd resistance point, it is at 4.32.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Adverum Biotechnologies Inc [NASDAQ:ADVM] is 0.65. As well, the Quick Ratio is 0.65, while the Cash Ratio is 0.58.
Transactions by insiders
Recent insider trading involved Soparkar Peter, CHIEF OPERATING OFFICER, that happened on May 15 ’25 when 2960.0 shares were sold. CHIEF DEVELOPMENT OFFICER, Seyedkazemi Setareh completed a deal on May 15 ’25 to sell 924.0 shares. Meanwhile, CEO, PRESIDENT AND DIRECTOR Fischer Laurent sold 9126.0 shares on May 15 ’25.
